Innovate and expand global cooperation to drive growth.

Adapting to a changing business environment and constantly reinventing themselves are solutions that SCIC-owned enterprises have implemented, thereby maintaining growth rates and achieving further success.

Ms. Han Thi Khanh Vinh, General Director of Vinapharm

Over the years, Vinapharm and its subsidiaries have proactively collaborated with numerous partners in developed countries with the aim of increasing the distribution of new, high-quality, and highly effective therapeutic products domestically, contributing to the development of Vietnam's pharmaceutical industry.

In the coming period, Vinapharm and its affiliated enterprises will continue to improve the quality of input factors; focus on investing in research and development; and strengthen international cooperation and linkages with pharmaceutical corporations in developed countries to enhance research capabilities and increase the technological and scientific content.

We propose the issuance/amendment of regulations on investment incentives, whereby enterprises and investment projects in the pharmaceutical industry, included in the list of prioritized investment sectors, will be subject to special investment incentives and support policies, without being constrained by the scale of investment capital as is currently the case; and to further improve the investment and business environment to encourage foreign investment in Vietnam in the pharmaceutical manufacturing sector…

Mr. Toshiyuki Ishii, member of the Board of Directors and CEO of Hau Giang Pharmaceutical Company.

"Meeting international standards and staying ahead of trends"

In the context of globalization, DHG Pharma Joint Stock Company must constantly innovate and apply advanced technologies to meet international standards and anticipate market trends. Investing in research and development (R&D), technology transfer, and new product development are key factors that help DHG Pharma maintain its position as a leading pharmaceutical company in Vietnam.

DHG Pharma has collaborated with Taisho (Japan) in technology transfer, exclusive product distribution, and the development of highly skilled human resources, as well as enhancing production capacity. These efforts have helped DHG Pharma maintain its leading position in the Vietnamese pharmaceutical industry and expand internationally. In particular, the support of SCIC will help DHG Pharma continue its sustainable development and improve its position in the domestic and international pharmaceutical markets.

Ms. Dao Thuy Ha, Member of the Board of Directors, Deputy General Director of Traphaco

"Breakthrough and powerful transformation"

After two years of restructuring with the orientation of "maintaining its number one position in traditional medicine - investing in the development of high-quality modern medicine," Traphaco has made a breakthrough and undergone a strong transformation.

Having become a shareholder of Traphaco in 2018, Daewoong and Traphaco have a strategic and comprehensive partnership in many areas, especially technology transfer. In addition, Traphaco invests heavily in quality control; research into first generic drugs…

Throughout its operations, the Company has consistently received support and assistance from SCIC, through its capital representatives who directly participate in governance, management, and the planning of medium and long-term development strategies.

Traphaco will continue to invest in research and development of high-end traditional and modern medicines, increase the number of new products, continue to develop key medicinal plant cultivation areas according to GACP – WHO standards, actively transfer technology, create a foundation for breakthroughs in pharmaceutical manufacturing technology, promote revenue growth, and expand market share…

Mr. Vu Anh Tuan, General Director of Bao Minh Corporation.

"Flexible and proactively adaptable"

In 2024, Bao Minh researched and launched new insurance products and strengthened its risk assessment and claims ratio control efforts.

In the coming period, the company will continue to closely monitor business operations; promote the application of information technology; improve the quality of services and customer care; diversify products; and expand its network…

Vietnam has integrated deeply into the global economy, so market impacts on businesses are unavoidable. To minimize these impacts, businesses must be truly flexible and proactive in adapting.

As of the end of September 2024, Bao Minh's total revenue reached VND 5,418 billion, an increase of 10.31% compared to the same period in 2023. Bao Minh continues to maintain its position as one of the top 3 non-life insurance companies in the Vietnamese insurance market.

Comment (0)